Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.

被引：0
|
作者：
Ghobrial, Irene M. [1 ]
Munshi, Nikhil [1 ]
Schlossman, Robert [1 ]
Chuma, Stacey [1 ]
Leduc, Renee [1 ]
Nelson, Marybeth [1 ]
Sam, Amy [1 ]
O'Connor, Kelly [1 ]
Harris, Brianna [1 ]
Warren, Diane [1 ]
Dollard, Akari M. [2 ]
Laubach, Jacob [1 ]
Vij, Ravi [3 ]
Campagnaro, Erica [4 ]
Birner, Ann [5 ]
Dixon-Lipscomb, Virginia
Anderson, Kenneth C. [1 ]
Richardson, Paul G. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] MMRC, Norwalk, CT USA
[3] Washington Univ, St Louis, MO USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1266 / 1266
页数：1
相关论文
共 50 条
  • [31] Clinical synergism of Bortezomib and chemotherapy in relapsed and refractory multiple myeloma.
    Mazumder, A
    Chauvin, E
    Curran, K
    Disperati, P
    Jagannath, S
    BLOOD, 2003, 102 (11) : 390B - 390B
  • [32] Phase I trial of bortezomib and Samarium Sm 153 lexidronam in refractory and relapsed multiple myeloma
    Berenson, James R.
    Patel, Ravi
    Yellin, Ori
    Swift, Regina A.
    CANCER INVESTIGATION, 2007, 25 : 33 - 33
  • [33] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
  • [34] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani
    Masaki Ri
    Chie Kato
    Takahiro Nakashima
    Nana Suzuki
    Shinya Hagiwara
    Takashi Kanamori
    Satsuki Murakami
    Arisa Masuda
    Shiori Kinoshita
    Takashi Yoshida
    Tomoko Narita
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2016, 103 : 316 - 321
  • [35] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Bortezomib is cost-effective for the treatment of relapsed and refractory multiple myeloma.
    Mehta, J
    Duff, S
    Gupta, S
    BLOOD, 2003, 102 (11) : 500A - 501A
  • [37] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Bagshaw, Meghan
    Schlossman, Robert
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Laubach, Jacob
    Jakubowiak, Andrzej J.
    Maiso, Patricia
    Roccaro, Aldo
    Armand, Philippe
    Dollard, Akari
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott
    Anderson, Kenneth C.
    Richardson, Paul G.
    LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
  • [38] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    S K Kumar
    B LaPlant
    V Roy
    C B Reeder
    M Q Lacy
    M A Gertz
    K Laumann
    M A Thompson
    T E Witzig
    F K Buadi
    C E Rivera
    J R Mikhael
    P L Bergsagel
    P Kapoor
    L Hwa
    R Fonseca
    A K Stewart
    A Chanan-Khan
    S V Rajkumar
    A Dispenzieri
    Blood Cancer Journal, 2015, 5 : e338 - e338
  • [39] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    Kumar, S. K.
    LaPlant, B.
    Roy, V.
    Reeder, C. B.
    Lacy, M. Q.
    Gertz, M. A.
    Laumann, K.
    Thompson, M. A.
    Witzig, T. E.
    Buadi, F. K.
    Rivera, C. E.
    Mikhael, J. R.
    Bergsagel, P. L.
    Kapoor, P.
    Hwa, L.
    Fonseca, R.
    Stewart, A. K.
    Chanan-Khan, A.
    Rajkumar, S. V.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e338 - e338
  • [40] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
    Galanis, E
    Buckner, JC
    Maurer, MJ
    Kreisberg, JL
    Ballman, K
    Boni, J
    Peralba, JM
    Jenkins, RB
    Dakhil, SR
    Morton, RF
    Jaeckle, KA
    Scheithauer, BW
    Dancey, J
    Hidalgo, M
    Walsh, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304
12345